5 Shifts to Customer-Centric Scientific Marketing

Sensitivity 99.8%. Interest 0%.

Five shifts toward customer-centric marketing in life sciences and diagnostics, from a scientist who used to believe good data sells itself.

I spent the first part of my career at the bench, convinced that strong data speaks for itself. Then I moved into marketing, and the first brochure I wrote proved me wrong.

It was a beautiful brochure. Sensitivity, specificity, limit of detection, time to result: every number we were proud of, lined up in a tidy column. I handed it to a lab manager at a congress booth. She skimmed it for about four seconds, set it down, and asked the one question none of my bullets answered: "Who on my team runs this at 2 a.m., and what happens when it fails?"

That question rewired how I think about my job.

Here's the uncomfortable math behind it. Gartner found that B2B buyers spend only about 17% of their buying journey meeting with suppliers, and that slice is shared by every vendor on the list. With three on the shortlist, each gets roughly 5% of the buyer's time (Gartner). A more recent Gartner survey found that 67% of B2B buyers would prefer a rep-free experience altogether (Gartner, 2026).

So your content does most of your selling, and it does it while you're not in the room.

In life sciences and diagnostics, that content usually speaks fluent product. Our customers speak workflow, risk, budget, and patients.

"Customer-centric" has become one of those phrases that shows up on every strategy slide and in very few brochures. So instead of a definition, here are five practical shifts I've seen make the difference, with examples from the industry and from my own, sometimes painful, learning curve.

Shift 1: From product specs to customer outcomes

Harvard marketing professor Theodore Levitt liked to tell his students: "People don't want to buy a quarter-inch drill. They want a quarter-inch hole." Every marketer has heard it. Very few of us in diagnostics actually write that way.

Our version of the drill is the spec sheet. Our version of the hole is something like a reliable result in the clinician's hands before the next ward round, or a validated workflow my weekend shift can run without calling me.

This matters more than ever because the people running the labs are stretched thin. The American Society for Clinical Pathology's 2024 Vacancy Survey found that U.S. lab vacancy rates, while lower than during the pandemic, are still above pre-COVID levels. Anatomic pathology departments reported vacancy rates above 28% (AABB summary of the ASCP survey).

In that world, "15 minutes hands-on time" isn't a spec. It's a staffing strategy. "Room-temperature storage" isn't a feature. It's one less freezer audit and one less thing to go wrong on a Friday evening.

A simple exercise I now run on every piece of copy is the so-what ladder:

1. Feature: fully automated extraction
2. So what? No manual pipetting steps
3. So what? Fewer handling errors and less training for new staff
4. So what? The lab can keep turnaround times stable even when it's short-staffed
5. So what? Patients get treated on the right drug sooner

Lead with rungs three to five. Keep rungs one and two as proof. Scientists still want the numbers; they just want to know why the numbers matter to them first.

Shift 2: From one buyer to a buying committee

We love to imagine a single customer: the brilliant lab director who reads our app note, gets excited, and signs the purchase order. That person rarely exists.

Forrester's 2024 State of Business Buying report found that, on average, 13 people are involved in a B2B purchase decision, and 89% of purchases cross two or more departments (Forrester). In diagnostics, the committee has a very particular cast. In many U.S. hospitals, new products go through a formal value analysis process, and some health systems run a dedicated Laboratory Value Analysis Committee (CentraCare).

Each person in that room is asking a different question:

• The lab director: Does it agree with my reference method, and will it pass inspection?
• The bench technologist: How many steps can I get wrong at the end of a long shift?
• The infectious disease physician: Will this change what I prescribe, and how fast?
• Procurement and finance: What's the total cost per reportable result, not just the list price?
• IT: Does it talk to our LIS, or is this another standalone island?

A single brochure can't answer five questions for five audiences. It ends up answering none of them well.

The practical shift is to map the committee before you write. For every major role, name the one question that would make them say no, and build one piece of content that answers it honestly. A one-page cost-per-result model for procurement. A short workflow video for the bench. A summary of clinical evidence for the physician.

The best compliment I ever got on a piece of sales material came from a sales colleague who said, "I can finally forward this to the person who's been blocking the deal."

Shift 3: From bold claims to earned trust

Scientists are trained skeptics. They read the methods section before the abstract, check the n, and look for the figure you didn't include. That instinct doesn't switch off when they open a marketing email.

Our industry also has the ultimate cautionary tale. Theranos promised to run a broad menu of tests from a few drops of blood and was once valued at around $9 billion. In 2022, its founder was sentenced to more than 11 years in prison for defrauding investors (Irish Times / Reuters). Nobody reading this is running a Theranos. But every overstated claim, every cherry-picked figure, and every "up to" in small print draws on the same account: the trust our customers place in diagnostics as a field.

The upside is that trust, once earned, is a powerful commercial asset. In the 2024 Edelman–LinkedIn B2B Thought Leadership Impact Report, 73% of decision-makers said an organization's thought leadership was a more trustworthy basis for judging its capabilities than its marketing materials (Edelman).

Trust is slow to build and quick to lose. I've come to believe it takes several good pieces of content to earn credibility with a scientific audience, and only one sloppy detail to lose it.

What earning it looks like in practice:

• Show your limitations. An application note that clearly states where a method wasn't tested reads as more credible, not less.
• Use real samples. Contrived spikes have their place, but clinical or field samples are what the reader actually works with.
• Let customers speak. A five-minute talk from a lab that uses your product beats any slide you could design.
• Teach before you sell. A webinar that explains a clinical problem, whether or not your product is the answer, builds more goodwill than ten product demos.

Shift 4: From talking at customers to listening with them

One of my favorite stories in healthcare design isn't about a diagnostic at all.

Doug Dietz, an industrial designer at GE Healthcare, went to a hospital to watch his new MRI scanner in action. Instead of a proud moment, he watched a frightened young girl who couldn't go through with her scan. Dietz later said he felt he had failed at his job (Milwaukee Magazine). He estimated that around 80% of children aged three to eight needed sedation to be scanned.

The technology inside the machine was excellent. The experience around it was the problem. So Dietz and his team talked to children, parents, and child-life specialists, and redesigned the scanner rooms as adventures: a spaceship, a pirate ship. Hospitals reported being able to scan more children, with patient volume up by about 7% (WUWM).

No spec sheet would have found that insight. Only watching people use the product did.

I had a smaller version of that moment during usability testing for a point-of-care system. We had spent weeks on a screen we thought was obvious. The first user hesitated, then pressed the wrong button. So did the second. The interface wasn't wrong in any engineering sense. It just didn't match how people actually think in a busy room with gloves on.

Customer-centric marketers treat every customer conversation as research. That includes booth chats, support tickets, lost deals, and the awkward question at the end of a webinar. Then they close the loop: they write it down, bring it to R&D, and show customers that something changed because they spoke up.

Marketing isn't only the company's voice. Done well, it's also the company's ears.

Shift 5: From launch day to adoption

Launch day feels like the finish line. The press release goes out, the booth looks great, the leads come in. In diagnostics, launch day is closer to the starting gun.

Consider Cepheid's Xpert MTB/RIF test for tuberculosis. The WHO endorsed it in December 2010 (Global Fund), and the clinical case was strong. But a great assay wasn't enough on its own; price per cartridge was a barrier for the countries that needed it most. In 2012, the Gates Foundation, PEPFAR, USAID, and Unitaid agreed a buy-down that cut the cartridge price from $16.86 to $9.98 for 145 high-burden countries (Stop TB Partnership).

The lesson for the rest of us: adoption depends on access, economics, training, and workflow fit, long after the launch campaign ends.

There's also a timing problem. Research by Professor John Dawes for LinkedIn's B2B Institute suggests that only about 5% of business buyers are in the market at any given time. The other 95% won't buy for months or years (Marketing Week). A lab that just signed a five-year contract won't care about your launch. But it will remember who helped it think through a problem when the contract comes up for renewal.

I learned this the honest way. A strong congress can generate well over a hundred leads in three days, and that feels like winning. The harder, more useful question comes months later: how many of those labs are now running samples routinely?

Adoption-focused marketing looks different:

• Onboarding content that gets a new lab to its first validated result fast
• Training that scales, such as short videos and quick-reference cards for the night shift
• Customer stories told in the customer's language, with their metrics
• Metrics beyond leads, such as time to routine use, repeat orders, and how often customers refer peers

The thread that ties them together

Look back at the five shifts and you'll notice they're really one idea seen from different angles. Outcomes over specs, committees over single buyers, evidence over hype, listening over broadcasting, and adoption over launch all come down to the same thing: treating the customer as the main character of the story, not the audience for ours.

That's harder in our field than almost anywhere else. Our products are complex, our claims are regulated, and our customers know the science as well as we do, sometimes better. But that's also why it works so well when we get it right. When a lab manager reads something and thinks "finally, someone who understands my Tuesday," the conversation that follows is a completely different one.

I keep a line on my own website that sums up how I try to work: Complexity, understood, becomes clarity. Clarity, shared, becomes value.

This is the first post in a series about scientific marketing, business development, and the long, very human road a diagnostic travels from the bench to routine use. I'm writing it the way I'd talk about it over coffee at a congress: openly, curiously, and still learning.

So, pull up a chair. I'd genuinely love to hear your side of it. Which of these shifts feels hardest where you work? Is there one you'd push back on, or a story that proves me wrong? Leave a comment, or send me a message on LinkedIn. No pitch and no agenda, just two people comparing notes. Those conversations are my favorite part of this work.